Search Results

This finding highlights GPR180 as a potential therapeutic target for metabolic disorders! This finding highlights GPR180 as a potential therapeutic target for metabolic disorders!

Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics

He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.

Research Labs 50+ Biotech Companies Who We Are We are a global network of scientists, biotech innovators, pharma

Everyone is welcome to present their work (students, postdocs, PI's, biotech, pharma companies)!

collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation

bases for ligand binding and efficacy to help optimize the design and engineering of more efficacious therapeutics perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

Waldhoer "I am a pharmacologist with a ~30 years background in academia and industry, working both in big pharma

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr.

The company works with clients from pharma, CROs, and academia, including MD Anderson and several leading

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

created by scientists, for scientists—bringing the global GPCR community together to advance biology and therapeutics Explore 200+ expert talks that bring GPCR discoveries to life From structural biology to therapeutics players in GPCR pharmacology and learn how agonists and antagonists shape efficacy, signaling, and therapeutic orthosteric drugs and uncover the power of allosteric modulators and kinetic insights to unlock new therapeutic Take the Next Step You're building the future of GPCR therapeutics.

In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically has been particularly interested in the role adhesion GPCRs play in glioblastoma biology and their therapeutic Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

Activation and Signaling March 15th, 2024 GPCRs in Immunology and Oncology November 17, 2023 GPCRs as Therapeutic

molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics